Insulin suppliers are facing pressures from the US administration to follow Eli Lilly’s lead and improve patient affordability for their medications, after the company implemented a $35 price cap on copays for its insulins for commercially insured and uninsured patients. The passing of the Inflation Reduction Act in August implemented a $35 cap on patient cost sharing for insulin in Medicare Part D, with Lilly’s latest move extending the benefit to all users of its insulin products.
President Joe Biden issued a statement praising the move. “For far too long,” he said “American families have been crushed by drug costs many times higher than what people in other countries are charged for the same prescriptions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?